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Background: The aim of this study was to evaluate the clinical characteristics of
nondiabetic nephropathy in type 2 diabetes mellitus patients and to ﬁnd a clinical
signiﬁcance of renal biopsy and immunosuppressive treatment in such a patient.
Methods: Renal biopsy results, clinical parameters, and renal outcomes were
analyzed in 75 diabetic patients who underwent kidney biopsy at Chungnam
National University Hospital from January 1994 to December 2010.
Results: The three most common reasons for renal biopsy were nephrotic range
proteinuria (44%), proteinuria without diabetic retinopathy (20%), and unexplained
decline in renal function (20.0%). Ten patients (13.3%) had only diabetic nephro-
pathy (Group I); 11 patients (14.7%) had diabetic nephropathy with superimposed
nondiabetic nephropathy (Group II); and 54 patients (72%) had only nondiabetic
nephropathy (Group III). Membranous nephropathy (23.1%), IgA nephropathy
(21.5%), and acute tubulointerstitial nephritis (15.4%) were the three most common
nondiabetic nephropathies. Group III had shorter duration of diabetes and lesser
diabetic retinopathy than Groups I and II (P¼0.008). Group II had the lowest
baseline estimated glomerular ﬁltration rate (P¼0.002), with the greatest propor-
tion of renal deterioration during follow-up (median 38.0 months, Po0.0001). The
patients who were treated with intensive method showed better renal outcomes
(odds ratio 4.931; P¼0.01). Absence of diabetic retinopathy was associated with
favorable renal outcome in intensive treatment group (odds ratio 0.114; P¼0.032).
Conclusion: Renal biopsy should be recommended for type 2 diabetic patients with
atypical nephropathy because a considerable number of these patients may have
nondiabetic nephropathies. And intensive treatment including corticosteroid or
immunosuppressants could be recommended for type 2 diabetic patients with
nondiabetic nephropathy, especially if the patients do not have diabetic retinopathy.
& 2013. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).n Society of Nephrology. Publi
c-nd/4.0/).
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The prevalence of type 2 diabetes mellitus is rapidly rising
worldwide [1]. The total number of people with diabetes
globally is projected to increase from 171 million in 2000
to 366 million in 2030 [2]. The burden of diabetes and itsshed by Elsevier. This is an open access article under the CC BY-NC-ND
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nephropathy (DN) is the leading cause of renal replacement
therapy and affects approximately 40% of type 1 and type
2 diabetic patients [3]. DN is also one of the most common
causes of renal replacement therapy disease in Korea (45.4%) [4].
However, not all nephropathies in diabetic patients are
due to DN. The prevalence of nondiabetic nephropathy (NN) is
presumed to exist in between one-sixth and two-thirds of
diabetic patients with overt proteinuria [5–8]. In Korea, Kim
et al. [9] reported 74 cases of renal biopsy performed in
diabetic patients, and nearly half of them had NN.
It is important to distinguish between NN and DN because
some NNs are reversible, whereas DN rarely improves. How-
ever, it is difﬁcult to differentiate between these two diseases
based on clinical ﬁndings alone. Renal biopsy is recommended
if diabetic patients present with an atypical course of nephro-
pathy. However, this procedure is invasive and might lead to
some complications.
Although several studies have been performed to evaluate
the prevalence and predictors of NN in diabetic patients, there
are no deﬁnitive indications for renal biopsy. In previous
studies, predictors of NN included evidence of acute renal
failure, microscopic hematuria, short duration of diabetes,
absence of retinopathy, or nephritic proteinuria [9–11].
We evaluated the prevalence and clinical characteristics
of NN in type 2 diabetes mellitus patients who underwent
renal biopsy. We analyzed the signiﬁcance of renal biopsy
and immunosuppressive treatment in NN with type 2 diabetes
mellitus patients.Methods
Data were collected retrospectively from medical records
at Chungnam National University Hospital. All patients were
diagnosed with type 2 diabetes mellitus prior to renal biopsy
or during the admission period. Our dataset included renal
biopsies from January 1994 to December 2010. Exclusion
criteria were as follows: (1) patients with kidney transplants
who had undergone renal biopsy for diagnosis of rejection;
(2) patients who had undergone renal biopsy for distinguish-
ing subtype of lupus nephritis; and (3) patients who had
undergone renal biopsy of renal tumors. Ninety-four diabetic
patients who underwent renal biopsy were screened, and 19
patients were excluded.
The reasons for renal biopsy were as follows: (1) nephrotic
range proteinuria (43 g/day) with atypical course of nephro-
pathy; (2) proteinuria without diabetic retinopathy [urine total
protein (TP)4500 mg/24 hours or spot urine TP/creatinine
(Cr)4500 mg/g]; (3) unexplained abrupt decline in renal
function [decrease to450% of estimated glomerular ﬁltration
rate (eGFR) or increase to4200% of serum creatinine within
1 month]; (4) unexplained hematuria (43/high power ﬁeld);
and (5) proteinuria with short duration of diabetes (24 hour
urine TP4500 mg or spot urine TP/Cr4500 mg/g within
5 years after diabetes diagnosis).
All biopsy specimens were obtained via percutaneous
needle biopsy and analyzed via light microscopy, electron micro-
scopy, and immunoﬂuorescence. All diagnoses were conﬁrmed
by the same experienced renal pathologist. DN was diagnosed
by the presence of mesangial expansion and diffuse inter-
capillary glomerulosclerosis with or without the nodular Kim-
melstiel–Wilson formation, basement membrane thickening,ﬁbrin caps, or capsular drops. Nondiabetic renal diseases were
categorized following orthodox pathological criteria.
Based on the biopsy ﬁndings, the patients were classiﬁed
into three groups: Group I (isolated DN); Group II [NN with
underlying DN (DN+NN)]; and Group III (isolated NN).
Patient characteristics analyzed included: age at biopsy, sex,
duration of diabetes (years), presence of diabetic retinopathy,
HbA1c (%), 24-hour urine total protein (mg/day), blood urea
nitrogen (BUN, mg/dL), serum creatinine (mg/dL), albumin
(g/L), triglyceride (mg/dL), total cholesterol (mg/dL), C-reactive
protein (CRP, mg/dL) as a marker of inﬂammation, comple-
ment (C3, C4, mg/dL), and immunoglobulin (Ig) G/A/M (mg/dL).
Estimated GFR (mL/min/1.73 m2) was calculated by Modiﬁca-
tion of Diet in Renal Disease (MDRD) equation. Baseline
characteristics and renal outcomes after the follow-up period
(decline of eGFR450% from baseline eGFR) were analyzed.
Baseline was deﬁned as the latest data prior to renal biopsy.
Patients with NN (Groups II and III; n¼65) were then
reclassiﬁed into two groups based on treatment modalities
(i.e., immunosuppressant or glucocorticoid therapy vs. conser-
vative measures).
Treatment modalities and renal outcomes in patients with
NN were analyzed. Renal outcomes were evaluated by changes
of eGFR and proteinuria. Treatment response group was
deﬁned as proteinuriao3.5 g/day and least 50% reduction
from initial value and stable renal function from baseline
(change in creatinineo25%), or improvement of eGFR450%
from baseline over a 6-month period of observation.
Statistical analysis
Collected data were processed using Microsoft Ofﬁce Excel
2010, IBM SPSS Statistics version 20, and PASW(Predictive
Analytics SoftWare) Statistics 18. Quantitative data are
expressed as mean7standard deviation. Negative or positive
values were expressed as count/total sample counts. Compar-
isons between groups were assessed using an unpaired t test,
analysis of variance, Chi-squared test, nonparametric test.
Relationships between baseline characteristics and renal out-
comes were assessed using binary univariate and multivariate
regression analysis. A P valueo0.05 was considered statisti-
cally signiﬁcant.Results
Reasons for renal biopsy
Seventy-ﬁve renal biopsies among 75 diabetic patients
were performed during the study period. Ten patients were
categorized into Group I (isolated DN), 11 patients into Group II
(DN+NN), and 54 patients into Group III (isolated NN).
The reasons for renal biopsy are shown in Table 1. Among
them, nephrotic range proteinuria with atypical course of
diabetic nephropathy was the most common (44.0%). Protei-
nuria without diabetic retinopathy and unexplained decline in
renal function were both ranked second (20.0%, each). The
other reasons for biopsy included unexplained microscopic
hematuria (13.3%) and proteinuria with short duration of
diabetes (2.7%; Table 1).
Patients with nephrotic range proteinuria with an atypical
course, proteinuria without diabetic retinopathy, unexplained
decline in renal function, or unexplained microscopic hematuria
Table 2. Baseline characteristics of type 2 diabetic patients who underwent renal biopsy
Parameter Group I (n¼10) Group II (n¼11) Group III (n¼54) P
Age (y) 65.0713.1n 53.2714.9 54.6714.1n NS
M:F ratio 9:1 10:1n 1.35:1n 0.024
DM duration (y) 8.377.5 9.677.9 4.274.8 0.008
Presence of DR 5/9 (55.6) 7/10 (70.0)n 11/46 (23.9)n 0.008
Laboratory data HbA1c (%) 7.1171.60 7.1771.30 6.8771.28 NS
24 h UP (mg/d) 5274.275749.5 4564.572354.6 4077.375372.6 NS
eGFR (mL/min/1.73m2) 51.0731.0 33.4721.1n 61.5731.9n 0.022
BUN (mg/dL) 26.3715.1n 42.4716.0n 26.8719.2n 0.037
Cr (mg/dL) 2.171.4 3.272.4 2.072.0 NS
Albumin (g/L) 3.271.1 2.970.7 3.271.0 NS
TG (mg/dL) 256.97126.7n 145.7755.9n 252.67237.9 NS
Total cholesterol (mg/dL) 224.7795.0 197.2749.5 234.37137.9 NS
CRP (mg/dL) 0.270.1 1.473.1 1.473.3 NS
C3 (mg/dL) 87.0719.4 103.4722.6 101.5730.6 NS
C4 (mg/dL) 36.679.0 36.979.4 30.7717.2 NS
IgG (mg/dL) 967.77375.9 1179.07535.4 1072.47537.8 NS
IgA (mg/dL) 273.77120.5 347.87194.6 304.57145.3 NS
IgM (mg/dL) 92.0765.0 126.6798.0 139.4777.4 NS
n Statistically signiﬁcant ﬁndings in analysis between two groups: between Groups I and II – serum BUN (P¼0.029), triglyceride (P¼0.025); between
Groups I and III – age at biopsy (P¼0.039); and between Groups II and III – sex (P¼0.036), presence of diabetic retinopathy (P¼0.016), baseline eGFR
(P¼0.002), serum BUN (P¼0.012).
Data are presented as mean7SD or positive count/total count (%).
BUN, blood urea nitrogen; Cr, creatinine; CRP, C-reactive protein; DM, diabetes mellitus; DR, diabetic retinopathy; Ig, immunoglobulin;
NS, nonsigniﬁcant value; UP, urine total protein.
Table 1. Reasons for renal biopsy in type 2 diabetic patientsn,y
Reason for renal biopsy Group I (n¼10) Group II (n¼11) Group III (n¼54) Pz
Nephrotic range proteinuria with atypical course (n¼33) 5 (15.2) 8 (24.2) 20 (60.6) 0.003
Proteinuria without diabetic retinopathy (n¼15) 2 (13.3) 1 (6.7) 12 (80.0) 0.001
Unexplained decline of renal function (n¼15) 1 (6.7) 1 (6.7) 13 (86.7) o0.001
Unexplained hematuria (n¼10) 1 (10.0) 1 (10.0) 8 (80.0) 0.007
Proteinuria with short duration of diabetes (n¼2) 1 (50.0) 0 (0) 1 (50.0) NS
n Differences in prevalence among the three groups were analyzed separately with nonparametric tests according to reason for biopsy.
y Group I: DN, Group II: DN+NN, Group III: NN.
z P¼0.514 by Fisher′s exact test.
Data are presented as n (%).
DN, diabetic nephropathy; NN, nondiabetic nephropathy; NS, nonsigniﬁcant value.
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to the DN or combined groups (Groups I and II).Baseline characteristics
Duration of diabetes (P¼0.008) and prevalence of diabetic
retinopathy (P¼0.008) were signiﬁcantly lower in Group III
compared to Groups I and II. The patients in Group II had the
lowest eGFR, whereas those in Group III had the highest level
of eGFR (P¼0.022). No other laboratory parameters showed
signiﬁcant differences (P40.05, Table 2).Results of renal biopsy
Table 3 presents the pathologic diagnoses and reasons for
renal biopsy in NNs (isolated DN is excluded from this table).
The three most common NNs were membranous nephropathy
(23.1%), IgA nephropathy (21.5%), and acute tubulointerstitial
nephritis (15.4%). Nephrotic range proteinuria was the most
common reason for renal biopsy in cases of membranous
nephropathy and IgA nephropathy. Unexplained decline of
renal function was the most common reason for renal biopsy
in acute tubulointerstitial nephritis.Renal outcomes and clinical characteristics in NN
The overall median follow-up duration was 38 months, and
those in Group I, Group II, and Group III were 23 months, 26
months, and 50.5 months, respectively. Group III had the best
long-term renal survival rate, and Group II had the worst long-
term renal survival rates. Renal deterioration was deﬁned as
decline the of eGFR450% from the baseline (Fig. 1).
Compared to the nonimproved renal outcome group, improved
renal outcome group showed lower prevalence of DN (P¼0.001),
more intensive treatment (P¼0.010, Tables 4 and 5).
Treatment modalities and renal outcomes in NNs
During the maximal follow-up (up to 5 years), 31 patients
were treated with intensive methods (i.e., immunosuppressants,
glucocorticoids, or combination therapy), and 22 patients
(70.9%) achieved improvement in renal function and pro-
teinuria. Thirty-four patients were treated with conservative
methods, and 13 patients (38.2%) achieved renal improvement.
Intensive treatment methods showed more favorable renal
outcome in univariate regression analysis. Long-term survival
did not show statistical signiﬁcant differences between the two
groups (P¼0.9315, Fig. 2).
Figure 1. Renal outcomes of patients during follow-up (median 38.0
months). Group 3 showed the best renal survival rate among the three
groups. Group II showed the largest proportion of renal deterioration
during follow-up [Po0.0001 by Log Rank (Mantel–Cox)]. Key: Group 1,
diabetic nephropathy; Group 2, underlying diabetic nephropathy+super-
imposed nondiabetic nephropathy; Group 3, nondiabetic nephropathy.
Table 4. Univariate (binomial) logistic regression analysis (NDRD
and renal outcome)n
Odds ratio 95% CI P
Age (y) 1.028 0.990–1.066 NS
DM duration (y) 0.904 0.816–1.001 NS
Presence of DR 0.360 0.112–1.155 NS
Presence of DN 0.053 0.006–0.447 0.007
Aggressive treatment 5.077 1.696–15.195 0.004
24 h UP (mg/d) 1.000 1.000–1.000 NS
HbA1c (%) 0.967 0.646–1.447 NS
eGFR (mL/min/1.73 m2) 0.100 0.997–1.031 NS
Albumin (g/L) 0.844 0.501–1.422 NS
TG (mg/dL) 1.003 0.999–1.007 NS
CRP (mg/dL) 1.083 0.887–1.322 NS
n Treatment response: proteinuria o3.5 g/day and least 50% reduction
from initial value, and stable renal function from baseline (change in
Cro25%), or improvement of eGFR450% from baseline over a 6-month
period of observation.
CI, conﬁdence interval; Cr, creatinine; CRP, C-reactive protein; DN,
diabetic nephropathy; DR, diabetic retinopathy; eGFR, estimated glo-
merular ﬁltration rate; NDRD, nondiabetic renal diseases; NS, not
signiﬁcant; TG, triglyceride; UP, urine total protein.
Table 5. Multivariate logistic regression analysis results (NDRD and
renal outcome)n
Odds ratio 95% CI P
Presence of DN 0.055 0.006–0.502 0.010
Aggressive treatment 4.931 1.464–16.611 0.010
n Treatment response: proteinuria o3.5 g/day and least 50% reduction
from initial value, and stable renal function from baseline (change in
creatinine o25%), or improvement of estimated glomerular ﬁltration
rate 450% from baseline over a 6-month period of observation.
CI, conﬁdence intervals; DN, diabetic nephropathy; NDRD, nondiabetic
renal diseases.
Table 3. Results of renal biopsy in nondiabetic nephropathyn
Pathology Total (n¼65) A B C D E
MN 15 (23.1) 8 (53.3) 5 (33.3) 0 (0) 1 (6.7) 1 (6.7)
IgA nephropathy 14 (21.5) 6 (42.9) 3 (21.4) 3 (21.4) 2 (14.3) 0 (0)
ATIN 10 (15.4) 4 (40.0) 1 (10.0) 4 (40.0) 1 (10.0) 0 (0)
FSGS 6 (9.2) 3 (50.0) 1 (16.7) 2 (33.3) 0 (0) 0 (0)
MCD 5 (7.7) 1 (20.0) 2 (40.0) 1 (20.0) 1 (20.0) 0 (0)
HSP nephritis 4 (6.2) 2 (50.0) 0 (0) 1 (25.0) 1 (25.0) 0 (0)
DPGN 3 (4.6) 1 (33.3) 1 (33.3) 0 (0) 1 (33.3) 0 (0)
MesPGN 2 (3.1) 1 (50.0) 0 (0) 0 (0) 1 (50.0) 0 (0)
ANCA-GN 2 (3.1) 0 (0) 0 (0) 2 (100.0) 0 (0) 0 (0)
HT nephropathy 2 (3.1) 0 (0) 0 (0) 1 (50.0) 1 (50.0) 0 (0)
MPGN 1 (1.5) 1 (100.0) 0 (0) 0 (0) 0 (0) 0 (0)
IgM nephropathy 1 (1.5) 1 (100.0) 0 (0) 0 (0) 0 (0) 0 (0)
n A, Nephrotic range proteinuria (43 g/day) with atypical course; B, Proteinuria without diabetic retinopathy [urine total protein (TP)4500 mg/day or
spot urine TP/Cr4500 mg/g]; C, Unexplained decline of renal function; D, Unexplained hematuria (43 red blood cells/high-power ﬁeld); E, Proteinuria
with short duration of diabetes (24 h urine TP4500 mg or spot urine TP/creatinine 4500 mg/g within 5 years of diabetes).
Data are presented as n (%).
ATIN, acute tubulointerstitial nephritis; DPGN, diffuse proliferative glomerulonephritis; FSGS, focal segmental glomerulosclerosis; GN, glomerulone-
phritis; HSP, Henoch–Schönlein purpura; HT, hypertensive; MCD, minimal change disorder; MesPGN, mesangial proliferative glomerulonephritis;
MN, membranous nephropathy; MPGN, membranous proliferative glomerulonephritis.
Figure 2. Renal outcomes of patients according to treatment mod-
ality (median 40.0 months). The patients who treated with intensive
methods showed slightly better renal survival rate than the patients
who treated with conservative methods [P¼0.9315 by Log Rank
(Mantel–Cox)].
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group (Group III) showed remarkable improvement in eGFR
at the 6-month follow-up period, even with a baseline eGFR4
15 mL/min/1.73m2. Two patients were diagnosed with focal
Table 6. Univariate (binomial) logistic regression analysis (NDRD
and renal outcome in intensive treatment group)n
Odd ratio 95% CI P
Age (y) 1.074 0.994–1.161 NS
DM duration (y) 0.940 0.798–1.109 NS
Presence of DR 0.114 0.016–0.828 0.032
Presence of DN 0.000 0.000 NS
24 h UP (mg/d) 1.000 1.000–1.000 NS
HbA1c (%) 1.376 0.606–3.123 NS
eGFR (mL/min/1.73 m2) 1.010 0.983–1.038 NS
Albumin (g/L) 1.701 0.531–5.450 NS
TG (mg/dL) 1.005 0.997–1.013 NS
CRP (mg/dL) 1.036 0.801–1.340 NS
n Treatment response: proteinuria o3.5 g/day and least 50% reduction
from initial value, and stable renal function from baseline (change in
creatinineo25%), or improvement of eGFR450% from baseline over a
6-month period of observation.
CI, conﬁdence intervals; Cr, creatinine; CRP, C-reactive protein; DN,
diabetic nephropathy; DR, diabetic retinopathy; eGFR, estimated glo-
merular ﬁltration rate; NDRD, nondiabetic renal diseases; NS, not
signiﬁcant; TG, triglyceride; UP, urine total protein.
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IgA nephropathy. One of the focal segmental glomerulosclerosis
patients received a combination therapy of corticosteroid,
rituximab, and mycophenolic acid, whereas the other patient
received corticosteroid only. The patient with IgA nephropathy
was treated with cyclophosphamide only. Group II patients
(DN+NN) did not show such a signiﬁcant improvement in eGFR.
Renal outcomes of intensive treatment group
We evaluated several factors to ﬁnd a prognostic factor
in NN in diabetes patients with intensive treatment. In the
intensive treatment group, clinical parameters, and renal
outcomes were analyzed using binomial logistic regression
(dependent variable: treatment response group). Absence
of diabetic retinopathy was associated with favorable renal
outcome in intensive treatment group (Table 6).Discussion
It is important to distinguish NN from DN because some
cases of NN are reversible, whereas DN is rarely improves.
Several clinical scenarios supportive of NN include rapidly
decreasing kidney function with or without increasing protei-
nuria (particularly if nephritic), active urinary sediment, evidence
of other systemic disease, absence of diabetic retinopathy, and
proteinuria in a type 1 diabetic patient witho5 years of disease
duration [12–14].
Although several studies have been performed to evaluate
clinical predictors of NN in diabetic patients, there is no
deﬁnitive indication for renal biopsy in diabetic patients with
proteinuria or declining renal function.
In this study, patients with isolated NN had a shorter
duration of diabetes and less diabetic retinopathy, consistent
with ﬁndings in preceding studies. The isolated NN group
also showed higher baseline eGFR compared to other groups,
which was not demonstrated in previous studies [8,9,15,16].
Chong et al. [10] suggested that the presence of diabetic
retinopathy and longer duration of diabetes may be predictors ofDN, whereas acute renal failure and microscopic hematuria may
be predictors of NN. Kim et al. [9] and Soni et al. [11] suggested
that a shorter duration of diabetes, absence of retinopathy, and
absence of nephritic proteinuria may be predictors of NN. Monga
et al. [17] analyzed superimposed glomerulopathies on diabetic
glomerulosclerosis (DGS) and suggested that duration of diabetes
favors superimposition of glomerulonephritis on DGS.
However, some studies did not show such correlations.
Hayashi et al. [18] analyzed renal biopsy specimens of Japanese
DM patients, and found that duration of DM was not associated
with all morphologic parameters. A study by Lin et al. [19]
demonstrated that diabetic retinopathy was not exclusively seen
in NN among type 2 DM patients. Mak et al. [20] suggested that
DN and NN were associated with similar durations of disease, as
well as incidences of retinopathy and neuropathy.
There were no statistically signiﬁcant differences between
our three study groups regarding age, HbA1c, creatinine level,
or 24-hour urine total protein. Our population characteristics
were similar to the study of NN in type II DM patients by
Zajjari et al. [21]. Mak et al. [20] also found that patients with
both isolated DN and NN had no difference in serum creatinine
or glycosylated hemoglobin levels. Ghani et al. [22] did not
ﬁnd signiﬁcant differences between DGS and NN groups
according to age or serum creatinine.
In this study, the prevalence of biopsy-proven NN in
diabetic patients was 86.7%, which was higher than previously
reported ﬁndings. The variety in reported prevalence of NN is
mainly due to a varying selection criteria for renal biopsy [5–
8,23]. Therefore, it may be helpful to collect more valuable
prognostic data.
Furthermore, renal outcomes in NN patients were analyzed
according to the treatment method. This emphasizes the
importance of conﬁrming the diagnosis of NN including via
renal biopsy in diabetic patients, as well as the application of
intensive treatments such as immunosuppressants or gluco-
corticoids. Wong et al. [8] suggested that the presence of DGS
is a risk factor for end-stage renal disease compared to NN.
Kim et al. [9] demonstrated that half of diabetic patients who
were treated with immunosuppressants achieved complete
remission of NN.
In this study, we observed impressively better renal outcomes
in patients who treated with intensive treatment including
corticosteroid or immunosuppressants. Compared to the nonim-
proved renal outcome group, improved renal outcome group
showed lower prevalence of diabetic nephropathy and more
intensive treatment. This suggests that intensive treatment includ-
ing corticosteroid or immunosuppressants should be recom-
mended for type 2 diabetic patients with NN, even though the
patients has poor initial renal function conﬁrmed at the diagnosis.
Absence of diabetic retinopathy was associated with favor-
able renal outcome in the intensive treatment group. It is
possible that absence of diabetic retinopathy is a prognostic
factor for a good effect of intensive treatment.
There are several limitations to this study. First, the retro-
spective study design allows for ﬁndings to be subject to many
other variables not analyzed in this study. Next, the number of
male patients was much higher than that of females, making our
results less generalizable. Further evaluation of predictors and
prognostic factor of NN such as larger multicenter prospective
trials or meta-analyses of existing studies might be helpful.
In conclusion, renal biopsy should be recommended for
type 2 diabetic patients with atypical nephropathy because a
considerable number of diabetic patients may have NNs that
Kidney Res Clin Pract 32 (2013) 115–120120are reversible. Intensive treatment including corticosteroid or
immunosuppressants could be recommended for type 2 dia-
betic patients with NN, especially if the patients do not have
diabetic retinopathy.Conﬂicts of interest
None.
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